


APOSTILLE

(CONVENTION DE LA HAYE DU 5 OCTOBRE 1961)

1. COUNTRY: UNITED STATES OF AMERICA
2. THIS PUBLIC DOCUMENT HAS BEEN SIGNED BY:
AMANDA L BLYTH
3. ACTING IN THE CAPACITY OF:
NOTARY PUBLIC OF NEW JERSEY
4. BEARS THE SEAL/STAMP OF:
AMANDA L BLYTH, NOTARY

CERTIFIED

5. AT TRENTON, NEW JERSEY
6. THE 23RD DAY OF MAY 2019
7. BY: Elizabeth Maher Muoio
State Treasurer
8. NO: A684583
9. SEAL/STAMP:
10. SIGNATURE



A handwritten signature in black ink, appearing to read "Elizabeth Maher Muoio".

Elizabeth Maher Muoio
State Treasurer

Certificate Number: 141425434

Verify this certificate at
https://www1.state.nj.us/TYTR_StandingCert/JSP/Verify_Cert.jsp

Clarke, Modet & C^o

COLOMBIA

PODER

Yo (nosotros), abajo firmante(s) _____
en mi (nuestro) carácter de representante(s) legales de

BIOSENSE WEBSTER (ISRAEL) LTD.

una sociedad organizada y existente de acuerdo con las leyes de **Israel**

y en actual cumplimiento de su objeto social, con domicilio 4 **Hatnufa Street, Yokneam, Israel 2066717**

por el presente instrumento confiero (conferimos) poder especial a favor de **CAROLINA MERCEDES DAZA MONTALVO**, con Cédula de Ciudadanía No. 66.783.790 de Palmira Valle, y Tarjeta Profesional. 141563 con domicilio en Bogotá, Colombia, para que actuando en su orden en nombre del (de la) otorgante le (la) representen ante cualquier entidad, autoridad y/o persona, especialmente ante las del orden Administrativo, Contencioso Administrativo, Judicial, Tribunales de Arbitramento y/o cualquier otro en lo referente a los siguientes asuntos:

- 1) Solicitar, tramitar, obtener y/o registrar cualquiera de las modalidades de Propiedad Industrial, tales como: patentes de invención, modelos de utilidad; diseños industriales, variedades vegetales; marcas, lemas, nombres y enseñanzas comerciales y denominaciones de origen; así como sus renovaciones, prórrogas, transferencias, cambios de nombre y/o domicilio, contratos y licencias.
- 2) Solicitar, tramitar, obtener y/o registrar derechos de autor, en cualquiera de sus presentaciones, así como la protección de secretos industriales y know-how.
- 3) Solicitar, tramitar, obtener y/o registrar registros sanitarios, adicionar o excluir importador, permisos y/o licencias de funcionamiento; así como sus renovaciones o prórrogas, transferencias, cambios de nombre y/o domicilio, contratos y licencias.
- 4) Ejercer acciones de oposición, observación, reclamos, reconsideración, reposición, apelación, cancelación administrativa o judicial, nulidad, protección al consumidor, concesión de licencias, protección de secretos industriales y demás acciones y recursos relacionados con derechos derivados de los asuntos arriba indicados y en contra de la competencia desleal, acciones derivadas de la obtención o explotación de licencias, acciones de indemnización de perjuicios. También podrá(n) intervenir en juicios civiles, comerciales, penales, contencioso-administrativos, tutelas y de policía; en acciones o juicios promovidos por el (la) mandante o en contra él (ella).
- 5) Registrar nombres de dominio ante la entidad competente.
- 6) En el ejercicio de este mandato los mandatarios arriba mencionados quedan facultados para: conciliar, cancelar, transigir, comprometer en árbitros, desistir, recibir y tomar

POWER OF ATTORNEY

I (we), the undersigned Louis J Cappezuto
legal representative(s) of

BIOSENSE WEBSTER (ISRAEL) LTD.

an organization existing under the laws of **Israel**

and in present execution of its business activity, domiciled 4 **Hatnufa Street, Yokneam, Israel 2066717**

do hereby grant POWER OF ATTORNEY to **CAROLINA MERCEDES DAZA MONTALVO** IA No. 66.783.790 of Palmira Valle, and Attorney ID No. 141563 residing in Bogotá Colombia, to act in the order of their appointment in behalf of grantor before any entity, authority and/or natural or juridical person, specially before those Administrative, Administrative-Contentious, Judicial, arbitration courts, and/or any other, in all matters concerning the following:

- 1) To apply, process, obtain and/or register any of the modalities of industrial property, such as: patents of invention, utility models; designs, plant varieties; trademarks, slogans, trade names, emblems and appellations of origin; as well as their renewals, time extensions, assignments, changes of name and/or domicile, agreements and licenses.
- 2) To apply, process, obtain and/or register copyrights of any kind as well as protection of industrial secrets or know-how.
- 3) To apply, process, obtain and/or register, health permits, add or exclude importers, operating authorizations and/or licenses; as well as their renewals, time extensions, or assignments, changes of name and/or domicile, agreements and licenses.
- 4) To bring actions of oppositions, observations, claims, reconsiderations, appeals or legal remedies, cancellations, nullity claims, consumer protection, granting of licenses, protection of trade secrets and other actions related with rights derived from the above-mentioned matters and against unfair competition acts, actions resulting from the obtaining or exploitation of licenses, recovering damages actions. They can also intervene or participate in Civil, Commercial, Criminal or Contentious-Administrative Trials; the actions for writ mandamus, police actions; in actions, lawsuits or litigations instituted by the grantor or against him.
- 5) To register domain names before the competent entity.
- 6) To the effect of this mandate the above-named proxy is empowered to: conciliate, cancel, settle, submit to arbitration, withdraw and to receive and take possession of the litigation related objet and waive or

Bogotá Colombia
Carrera 11 N° 86-53 Piso 3
Tel: (57 1) 6181088 · Fax: (57 1) 6350824
Email: info@clarkemodet.com.co

posesión de la cosa objeto de litigio y renunciar o desistirse a derechos concedidos o en curso de concesión, admitir los hechos del proceso.

7) Ratificar o no la agencia oficiosa.

8) Así mismo faculto (facultamos) a los mencionados apoderados para recibir notificaciones y designar apoderados judiciales o extrajudiciales, sustituir el presente poder y revocar las sustituciones que hicieren.

renounce the rights granted or in process of granting, admit the facts of the case.

7) To ratify or not the officious agency.

8) I (we) hereby appoint the above mentioned attorney with powers to receive notifications and to designate judicial and extrajudicial attorneys, substitute this Power of Attorney and to revoke such substitutions.

Dado y firmado en _____

Granted and signed at New Brunswick, NJ USA

a los _____ días de _____

on this 17th day of MAY of 2019




Firma / Signature

Louis J Capezzuto
Assistant Secretary



AMANDA LIN BLYTH
NOTARY PUBLIC OF NEW JERSEY
My Commission Expires 10/28/2023

PA 2044323



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

21 de mayo de 2019

POR LA PRESENTE SE CERTIFICA QUE EL DOCUMENTO ADJUNTO ES UNA COPIA FIEL DE LOS REGISTROS DE LA OFICINA DE PATENTES Y MARCAS DE LOS ESTADOS UNIDOS DE DICHS DOCUMENTOS DE LA SOLICITUD DE PATENTE IDENTIFICADA A CONTINUACIÓN QUE CUMPLIÓ CON LOS REQUISITOS PARA QUE SE LE OTORGARA UNA FECHA DE PRESENTACIÓN EN VIRTUD DE 35 USC 111.

NÚMERO DE SOLICITUD: *15/986.109*

FECHA DE PRESENTACIÓN: *22 de mayo de 2018*

EL CÓDIGO DE PAÍS Y EL NÚMERO DE SU SOLICITUD DE PRIORIDAD, QUE SE USARÁ PARA LA PRESENTACIÓN EN EL EXTRANJERO EN VIRTUD DE LA CONVENCIÓN DE PARÍS, ES *US15/986.109*

Por autoridad del
Subsecretario de Comercio para la Propiedad Intelectual
y Director de la Oficina de Patentes y Marcas de los Estados Unidos




R GLOVER

Funcionario certificador

REIVINDICACIONES

1. Un método para producir un implante, el método comprende:
proporcionar una cubierta biocompatible hueca para implantarse en un órgano de un paciente;
- 5 inyectar, en una o más ubicaciones en la cubierta, al menos dos materiales de relleno, en donde una mezcla de al menos dos de los materiales de relleno se configura para producir burbujas de gas dentro de un volumen de la mezcla; y
 formar las burbujas de gas en los materiales de relleno inyectados al
10 calentar la cubierta que contiene la mezcla de los materiales de relleno inyectados.
2. El método de acuerdo con la reivindicación 1, en donde inyectar los materiales de relleno comprende mezclar los al menos dos de los materiales de relleno para producir la mezcla fuera de la cubierta, e inyectar la mezcla producida en una o más ubicaciones en la cubierta.
- 15 3. El método de acuerdo con la reivindicación 1, en donde inyectar los al menos dos materiales de relleno comprende inyectar cada uno de los materiales de relleno separadamente dentro de la cubierta.
4. El método de acuerdo con la reivindicación 1, en donde uno de los al menos dos materiales de relleno comprende un polímero de silicona.
- 20 5. El método de acuerdo con la reivindicación 1, en donde formar las burbujas de gas comprende calentar la cubierta a una temperatura mayor que 100 °C.

6. El método de acuerdo con la reivindicación 1, y que comprende cementar la mezcla a una superficie interna de la cubierta al calentar la cubierta.
7. El método de acuerdo con la reivindicación 1, en donde la mezcla se encuentra en un estado líquido antes de formar las burbujas de gas, y en
5 donde calentar la cubierta comprende curar la mezcla del estado líquido a un estado sólido.
8. El método de acuerdo con la reivindicación 1, en donde inyectar los al menos dos materiales de relleno comprende inyectar un primer volumen de los al menos dos materiales de relleno en una primera ubicación en la cubierta, e
10 inyectar un segundo volumen diferente de los al menos dos materiales de relleno en una segunda ubicación diferente en la cubierta.
9. El método de acuerdo con la reivindicación 1, y que comprende inyectar un material de relleno adicional en una ubicación adicional en la cubierta, de tal manera que la mezcla del material de relleno cubra al menos parte de una
15 superficie interna de la cubierta.
10. El método de acuerdo con la reivindicación 9, en donde inyectar el material de relleno adicional comprende inyectar gel de silicona.
11. Un implante, que comprende:
una cubierta biocompatible hueca; y
20 al menos dos materiales de relleno,
en donde la cubierta se configura para implantarse en un órgano de un paciente, y para contener los materiales de relleno, y en donde al menos dos de los materiales de relleno se configuran para mezclarse entre sí y producir

burbujas de gas dentro de un volumen de una mezcla de al menos dos de los materiales de relleno.

12. El implante de acuerdo con la reivindicación 11, en donde uno de los al menos dos materiales de relleno comprende un polímero de silicona.

5 13. El implante de acuerdo con la reivindicación 11, en donde los al menos dos de los materiales de relleno se configuran para mezclarse entre sí y para producir las burbujas de gas a una temperatura mayor que 100 °C.

14. El implante de acuerdo con la reivindicación 11, en donde la mezcla se configura para adherirse a una superficie interna de la cubierta.

10 15. El implante de acuerdo con la reivindicación 11, en donde la mezcla se configura para estar en un estado líquido antes de producir las burbujas de gas y, cuando se producen las burbujas de gas, para cambiar de estado del estado líquido a un estado sólido.

P-2019/20488

SUPERINTENDENCIA DE INDUSTRIA Y COMERCIO
DIRECCIÓN DE NUEVAS CREACIONES

E. S. D.

Ref.: Expediente No. **NC2019/0005174**
Solicitud de registro de patente de invención a nombre de **BIOSENSE WEBSTER (ISRAEL) LTD**


Yo, CAROLINA DAZA MONTALVO, identificada como aparece al pie de mi firma, domiciliada en la Carrera 11 No. 86-53, piso 3, obrando como apoderada de la solicitante de la patente de invención de la referencia **BIOSENSE WEBSTER (ISRAEL) LTD**, en respuesta al Oficio No. 3184 del 27 de mayo de 2019, atentamente me permito presentar el siguiente documento:

1. **Cesión:** Se allega a este Despacho la cesión de derechos de los inventores a la sociedad solicitante, junto con su respectiva traducción.
2. **Poder:** Así mismo, se anexa el poder debidamente otorgado por **BIOSENSE WEBSTER (ISRAEL) LTD**.
3. **Prioridad:** Por último, se allega la copia certificada de la solicitud de la cual se reivindica la prioridad.

Habiendo dado cumplimiento al requerimiento de este Despacho, solicito respetuosamente se continúe con el trámite de la referencia.

Atentamente,


CAROLINA DAZA MONTALVO
C.C. 66.783.790 de Palmira Valle
TP-141563 CSJ
notificaciones@clarkemodet.com.co



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

May 21, 2019

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: *15/986,109*

FILING DATE: *May 22, 2018*

THE COUNTRY CODE AND NUMBER OF YOUR PRIORITY APPLICATION, TO BE USED FOR FILING ABROAD UNDER THE PARIS CONVENTION, IS *US15/986,109*

By Authority of the
Under Secretary of Commerce for Intellectual Property
and Director of the United States Patent and Trademark Office



R GLOVER
Certifying Officer

Electronic Acknowledgement Receipt	
EFS ID:	32690860
Application Number:	15986109
International Application Number:	
Confirmation Number:	3330
Title of Invention:	A LIGHTWEIGHT BREAST IMPLANT
First Named Inventor/Applicant Name:	Assaf Govari
Customer Number:	27777
Filer:	Eugene L Szczecina/Joy Katalan
Filer Authorized By:	Eugene L Szczecina
Attorney Docket Number:	BIO5896USNP
Receipt Date:	22-MAY-2018
Filing Date:	
Time Stamp:	14:19:27
Application Type:	Utility under 35 USC 111(a)

Payment information:	
Submitted with Payment	yes
Payment Type	DA
Payment was successfully received in RAM	\$1880
RAM confirmation Number	052318INTEFSW00000544100750
Deposit Account	100750
Authorized User	Joy Katalan
The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows: 37 CFR 1.16 (National application filing, search, and examination fees) 37 CFR 1.17 (Patent application and reexamination processing fees)	

37 CFR 1.19 (Document supply fees)					
37 CFR 1.20 (Post Issuance fees)					
37 CFR 1.21 (Miscellaneous fees and charges)					
File Listing:					
Document Number	Document Description	File Name	File Size(Bytes)/ Message Digest	Multi Part /.zip	Pages (if appl.)
1		BIO5896USNP_SPECIFICATION_EFS_20180522.pdf	216451	yes	19
			6479ba89a5412588e3e77e6247d9cad90c04ee72		
	Multipart Description/PDF files in .zip description				
	Document Description		Start	End	
	Abstract		19	19	
	Claims		16	18	
	Specification		1	15	
Warnings:					
Information:					
2	Application Data Sheet	BIO5896USNP_ADS_EFS_20180522.pdf	1255948	no	8
			7fa3be861dea15165dca2cc56c99d2bdc4c2e5f		
Warnings:					
Information:					
3	Information Disclosure Statement (IDS) Form (SB08)	BIO5896USNP_IDS_EFS_20180522.pdf	1034350	no	4
			8f96dfd7421c32f84adb16709608dd2917e6f4f3		
Warnings:					
Information:					
4	Power of Attorney	BIO5896USNP-POA.pdf	177155	no	4
			ff55dce65c58c4ffc065c500628f3a9534a72833		
Warnings:					
Information:					
5	Drawings-only black and white line drawings	BIO5896USNP_Drawings.pdf	250321	no	2
			968f2667f9c38fb029fd71acc7475c761cea823d		

Warnings:					
Information:					
6	Fee Worksheet (SB06)	fee-info.pdf	36844	no	2
			f67a2a7c4b3f6142ed40c367638611e2497ab6ed		
Warnings:					
Information:					
Total Files Size (in bytes):			2971069		
This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503. <u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application. <u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course. <u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.					

A LIGHTWEIGHT BREAST IMPLANT

FIELD OF THE INVENTION

The present invention relates generally to breast implants, and particularly to methods and devices for
5 breast implants having reduced weight.

BACKGROUND OF THE INVENTION

Various types of implants, such as breast implants, are used in a variety of therapeutic and cosmetic applications.

10 For example, U.S. Patent Application Publication 2016/0369100 describes compositions for forming silicone elastomers thereby which have improved characteristics and which can be used for medical devices. The composition for forming a silicone elastomer can include (A) an
15 organopolysiloxane having silicon-bonded alkenyl groups, (B) an organohydrogensiloxane having an average of two or more silicon-bonded hydrogen atoms in the molecule, (C) an inorganic filler, and (D) a filler treatment agent which includes an alkenyl-containing group.

20 U.S. Patent Application Publication 2011/0270391 describes an inflatable tissue expander or more permanent prosthesis, suitable for implantation in a breast. The tissue expander includes a puncturable, self-sealing anterior portion forming a fillable cavity, and posterior
25 portion that is puncture resistant.

SUMMARY OF THE INVENTION

An embodiment of the present invention that is described herein provides a method for producing an implant, the method includes providing a hollow
30 biocompatible shell to be implanted in an organ of a

patient. At least two filling materials are injected at one or more locations in the shell, such that a mixture of at least two of the filling materials is configured to produce gas bubbles within a bulk of the mixture. The gas bubbles
5 are formed in the injected filling materials by heating the shell containing the mixture of the injected filling materials.

In some embodiments, injecting the filling materials includes mixing the at least two of the filling materials
10 to produce the mixture outside the shell, and injecting the produced mixture at the one or more locations in the shell. In other embodiments, injecting the at least two filling materials includes injecting each of the filling materials separately into the shell. In yet other embodiments, one
15 of the at least two filling materials includes a silicone polymer.

In an embodiment, forming the gas bubbles includes heating the shell to a temperature above 100⁰C. In another embodiment, the method includes cementing the mixture to
20 an inner surface of the shell by heating the shell.

In some embodiments, the mixture is at a liquid state prior to forming the gas bubbles, and heating the shell includes curing the mixture from the liquid state to a solid state. In other embodiments, injecting the at least
25 two filling materials includes injecting a first volume of the at least two filling materials at a first location in the shell, and injecting a second different volume of the at least two filling materials at a second different location in the shell.

30 In an embodiment, the method includes injecting an additional filling material at an additional location in the shell, such that the mixture of the filling material

covers at least part of an inner surface of the shell. In another embodiment, injecting the additional filling material includes injecting silicone gel.

There is additionally provided, in accordance with an embodiment of the present invention, an implant that includes a hollow biocompatible shell and at least two filling materials. The shell is configured to be implanted in an organ of a patient, and to contain the filling materials, and at least two of the filling materials are configured to mix with one another and to produce gas bubbles within a bulk of a mixture of the at least two of the filling materials.

The present invention will be more fully understood from the following detailed description of the embodiments thereof, taken together with the drawings in which:

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a schematic, pictorial illustration of breast implant implanted in a woman's breast, in accordance with embodiments of the present invention;

Fig. 2A is a schematic, pictorial illustration of filling material injected into a breast implant, in accordance with embodiments of the present invention;

Fig. 2B is a schematic, pictorial illustration of a breast implant, in accordance with embodiments of the present invention; and

Fig. 3 is a flow chart that schematically illustrates a method for producing a breast implant, in accordance with an embodiment of the present invention.

DETAILED DESCRIPTION OF EMBODIMENTS

OVERVIEW

Medical implants, such as breast implants, are typically used for reconstructing a human breast after excision or for shaping the size and contour of breasts in cosmetic applications. A conventional breast implant is typically filled with some filling material, such as silicone gel that conforms to the texture of natural tissue of the breast. The implant further comprises a biocompatible shell adapted to encapsulate the filling material and to be implanted in the human breast so as to conform to the texture of the breast tissue.

A breast implant is desirably required to be lightweight and at the same time firm. A breast implant filled with a large amount of silicone gel, however, typically has excess weight, which may cause inconvenience and even medical problems such as back ache.

Embodiments of the present invention that are described hereinbelow provide a lightweight breast implant that conforms to the texture of natural tissue of the breast, as well as methods for producing this breast implant. In some embodiments, two or more filling materials, such as a silicon elastomer and one or more other types of silicone polymers, are injected into a hollow biocompatible shell to be implanted in a patient breast. The filling materials may be mixed together before being injected into the shell, or alternatively mixed within the shell.

The mixture produced from the filling materials is typically formed in a liquid state, e.g., emulsion, and is configured to produce gas bubbles within a bulk of the

mixture, in response to heating the shell including the mixture.

In some embodiments, the mixture is heated to 150°C and subsequently cooled to room temperature (e.g., 25°C) in
5 a curing process that induces the formation of the gas bubbles in the bulk of the filling material. The curing process and bubble formation are configured to shape the filling material in a form of a solid sponge having a smooth outer surface (i.e., without pores or having the pores
10 closed). The curing process is further configured to cement the sponge to the inner surface of the biocompatible shell so as to produce the implant as a single firm unit.

In some embodiments, the implant may comprise filling materials additional to the mixture materials, such as
15 silicone gel used in conventional implants, which is inserted into the shell and is later wrapped with the sponge-shaped filling material in accordance with the process described above.

Filling materials may be injected into the shell at
20 one or more selected locations, so as to shape the contour of the implanted breasts and optimize the overall weight of the implant. For example, a breast implant may comprise a thick layer of filling material at the base of the implant, and a thinner layer of the same filling material
25 at the front of the implant.

The disclosed techniques provide the implanted patient with a lightweight yet firm breast implant that conforms to the texture of natural tissue of the breast. Furthermore, the disclosed techniques provide a physician,
30 such as a plastic surgeon, with a flexibility to optimize the weight of the implant without compromising the overall size, shape and texture of the implanted breast.

SYSTEM DESCRIPTION

Fig. 1 is a schematic pictorial illustration of a breast implant 20 implanted in a woman's breast 22, in accordance with an embodiment of the present invention.
5 Typically, implant 20 is a prosthesis used for shaping the size and contour of breast 22.

Breast 22 comprises natural tissue 28 surrounding implant 20. In some embodiments, implant 20 comprises a hollow biocompatible shell 24, made from silicone or any
10 other suitable material, which is configured to encapsulate soft filling materials that resemble the texture of tissue 28.

In an example embodiment, shell 24 comprises gel 26, made from silicone or any other suitable material, and
15 adapted to serve as filling material of implant 20.

In some embodiments, shell 24 comprises a porous material, referred to herein as a sponge 30, made from a mixture of two or more suitable materials. In example
20 embodiments, the mixture of materials is produced by blending a silicone polymer, such as a silicone elastomer (e.g., Nusil Med 4805, Shore hardness A7) with another type of silicone polymer (e.g., Nusil Med 4-4800), both of these materials are provided, for example, by NuSil™ Technology LLC, 1050 Cindy Lane, Carpinteria, CA 93013.

25 In some embodiments, sponge 30 comprises gas bubbles 33 located in the bulk of the sponge. Sponge 30 comprises an outer surface 32, which has a smooth texture without any pores, in which the pores are closed.

In some embodiments, shell 24 is physically and
30 chemically stable, so as to create a sustainable physical insulation between sponge 30 and tissue 28. Furthermore,

sponge 30 and the inner surface of shell 24 are well cemented to one another. In other words, sponge 30 is configured to adhere to the inner surface of shell 24.

5 In some embodiments, the formation of gas bubbles 33, instead of the silicone gel, reduces the weight of implant 20, while still providing firm texture of sponge 30 so as to obtain the required shape and contour of breast 22.

10 In some embodiments, the portion and distribution of sponge 30 within implant 20 is controllable, as will be described in Figs. 2A and 2B below. In the example of Fig. 1, sponge 30 is designed thicker at a base 46 (e.g., located at the lower part) of breast 22, compared to the thickness of sponge 30 at a front area 48 and at an upper area 50 of breast 22.

15 In the example of Fig. 1, gel 26 is inserted or injected into an inner section of the inner volume of shell 24, whereas filling material 40 is injected into an outer section of the inner volume of shell 24.

20 In another example, filling material 40 is injected into the inner section of shell 24, and gel 26 is injected at the outer section of shell 24, so that at least part of the inner surface of shell 24 is in direct contact with gel 24.

25 The configuration of implant 20 shown in Fig. 1 is an example configuration that is shown purely for the sake of conceptual clarity. In alternative embodiments, any other suitable configuration can be used. For example, implant 20 may comprise filling material solely made from sponge 30, without gel 26.

30 Furthermore, embodiments of the present invention are by no means limited to a specific geometry, types of filling

materials, and number of interfaces within the fillings materials and between the filling materials and the shell.

Embodiments of the present invention are also not limited to this specific type of implant. The principles
5 described herein may similarly be applied to other suitable types of medical and aesthetic implants.

Fig. 2A is a schematic, pictorial illustration of filling material 40 injected into breast implant 20, in accordance with embodiments of the present invention. In
10 some embodiments, filling material 40 may comprise any suitable mixture of two or more materials, such as the silicone elastomer (which is a silicone polymer) and one or more other types of silicone polymers described in Fig. 1 above.

15 In some embodiments, the silicone elastomer and the other silicone polymers are mixed, before being injected into shell 24, using any suitable blending machine. The mixture forms filling material 40, which is later injected into implant 20. In alternative embodiments, at least two
20 materials of filling material 40 are injected into implant 20 separately, and are mixed within the shell during a later process step of filling material 40, as will be described in Fig. 2B below.

In some embodiments, the materials comprising filling
25 material 40 are injected into implant 20 using a syringe 44. In the example of Fig. 2A, the injection is carried out by puncturing a small hole in implant 20. In other embodiments, implant 20 may comprise one or more valves, so that the materials comprising filling material 40 are
30 inserted into implant 20 using syringe 44 or any other suitable mechanism without puncturing shell 24.

The following embodiments describe the process steps of injecting filling material 40 into implant 20. These embodiments are also applicable for separately injecting at least two materials comprising filling material 40, using a sequence of two or more respective injection process steps, and for inserting these materials using any other suitable insertion method.

As described in Fig. 1 above, filling material 40 may be injected into implant 20 at one or more locations, whereas the amount of injected material may differ among the locations. In the example of Fig. 2A, filling material 40 is injected at three locations. The largest amount of filling material 40 is injected into base 46 of implant 20, a smaller amount is injected into front area 48 and the smallest amount is injected into upper area 50 of implant 20. The plurality of injections at respective locations may undesirably form separate chunks of filling material 40 coupled to one another at one or more interfaces 52. This issue is addressed further below.

In other embodiments, the injection may be carried out using any other suitable number of locations, and any suitable amount of filling material(s) injected at each location. Furthermore, the portion of gel 26 may vary between zero and any suitable percentage of the inner volume of implant 20. The portion of filling material 40 injected at each location and the volumetric ratio between gel 26 and filling material 40 determines the size, shape and weight of implant 20.

In some embodiments, filling material 40 may be injected at one or more locations of shell 24 and gel 26 may be inserted into shell 24 at a later stage of the

production process as will be described in Fig. 2B and Fig. 3 below.

Fig. 2B is a schematic, pictorial illustration of breast implant 20, in accordance with an embodiment of the present invention. Fig. 2B depicts implant 20 after applying to the implant one or more thermal process steps subsequently to the process steps described in Fig. 2A above.

In some embodiments, implant 20 as described in Fig. 2A, is heated to a suitable temperature using a sequence of one or more thermal process steps, also referred to herein as a curing process. The thermal process steps may be carried out using any suitable sequence of heating and cooling cycles. In an example embodiment, the thermal process may comprise a single heating step, starting at room temperature (e.g., 25°C) and heating up to an exemplary temperature of 150°C. In other embodiments, the maximal heating temperature of the thermal process may comprise any suitable temperature between 100°C and 200°C.

In some embodiments, the curing process changes the matter phase of filling material 40 to sponge 30 by locally forming gas bubbles 33 trapped in the bulk of sponge 30. In an example embodiment, filling material 40 is heated to 150°C and subsequently cooled to room temperature (25°C). Such a thermal cycle transforms filling material 40 from a liquid state (e.g., emulsion) into a solid state.

During the formation of sponge 30 from filling material 40, the filling material may evaporate at specific locations, resulting in the formation of gas bubbles 33 that form the structure of sponge 30. Note that the gas bubbles produced during the curing process may contain

byproducts of filling material 40, or air and/or other gases absorbed from the environment during various process steps of implant 20, or a combination thereof.

5 In some embodiments, the bubble size and the distribution of gas bubbles 33 in space may be determined by the sequence of the curing process, and by the composition and structure of the materials comprising filling material 40.

10 Note that bubbles 33 are formed solely in the bulk of sponge 30, whereas surface 32 of sponge 30 remains flat and smooth, e.g., without pores. The combination of high temperature (e.g., 150°C) and smoothness of surface 32, enables cementing between surface 32 of sponge 30 and an inner surface of shell 24. In an embodiment, the curing
15 process eliminates interfaces 52 by forming a contiguous bulk of sponge 30 distributed across implant 20 as shown in Figs. 1 and 2B.

In alternative embodiments, at least two of the materials comprising filling material 40 are injected
20 separately into implant 20 and the thermal process causes these materials to be mixed together into a mixture within the implant, for example by a thermal-driven diffusion process or using any other suitable thermal-related mechanism.

25 In some embodiments, gel 26, or any other suitable material instead of or in addition to gel 26, may be inserted into shell 24 after the formation of sponge 30. These embodiments allow using any suitable filling materials that cannot withstand high temperatures, such as
30 150°C. By injecting filling material 40 at selected locations of shell 24, sponge 30 is formed at these selected locations, and gel 26 and/or other materials may be

injected into shell 24 thereafter so as to fill the desired volume of shell 24.

Fig. 3 is a flow chart that schematically illustrates a method for producing breast implant 20, in accordance with an embodiment of the present invention. The method begins with preparing filling material 40, which is a mixture of a silicone polymer, such as a silicone elastomer (e.g., Nusil Med 4805, Shore hardness A7 or A5) blended with another type of silicone polymer (e.g. Nusil Med 4-4800,) at a materials blending step 100. Note that filling material 40 may be in the form of a liquid having high viscosity, such as an emulsion.

In some embodiments, the mixing process of step 100 may be carried out by a manufacturer, such as NuSil™ Technology LLC, and delivered as a mixture to the producer of implant 20. In another embodiment, at least two of the materials of filling material 40 are provided as separate materials, to be blended at step 100 by the manufacturer of implant 20.

At an injection step 102, the mixture of materials comprising filling material 40 is injected at one or more locations in shell 24. The injection may be carried out using syringe 44 or any other suitable device. As depicted in Fig. 2A above, different portions of filling material may be injected at different locations of implant 20. In alternative embodiments, at least two materials of filling material 40 are not mixed at step 100, and, at step 102, are injected separately into shell 24 using a sequence of two or more respective injection operations.

In some embodiments, shell 24 may contain, instead of or in addition to, silicone gel 26 any other suitable material, such as saline solutions. These materials may be

inserted before or after performing step 102, so that the injection locations of filling material 40 are selected to obtain the desired shape and texture of breast 22. In the example of Fig. 2A, filling material 40 is injected as a buffering layer between gel 26 the outer-facing areas of shell 24, such as base 46, front area 48 and upper area 50. Note that filling material 40 may be injected at selected locations of shell 24, before inserting gel 26 into shell 24.

At a thermal processing step 104, implant 20 is heated from room temperature (e.g., 25°C) to 150°C or even a higher temperature and then cooled to room temperature. During the thermal process the emulsion of filling material 40 is transformed from liquid state into a solid state so as to form sponge 30.

During step 104, filling material 40 evaporates at specific locations having evaporation temperature lower than of the bulk of material 40. The local evaporations form across the bulk of material 40, gas bubbles 33 that define the structure of sponge 30. In some embodiments, thermal processing step 104 further results in cementing between surface 32 and the inner surface of shell 24.

In other embodiments, silicone gel 26 may be injected after the completion of processing step 104. The injection of gel 26 after thermal processing step 104 may prevent any heating-related damage to gel 26 associated with the thermal process. This sequence may allow using other filling materials that are susceptible to temperatures substantially higher than 37°C (body temperature), such as 150°C. Furthermore, after step 104, other materials such as saline solution, may be injected instead of or in addition

to gel 26. In some embodiments, step 104 concludes the production process of implant 20. Note that steps 100, 102 and 104 are depicted purely by way of example for the sake of simplicity and clarity. In other embodiments, each of these steps may comprise sub-steps. Moreover, the production process of implant 20 may comprise additional steps, such as a step of repairing the small holes punctured, at step 102, by needle 42 of syringe 44. The repairing of the holes may be carried out at one or more additional process steps, or at step 104.

At an implantation step 106, implant 20 is delivered to a physician, such as a plastic surgeon, who carries out the implantation procedure of implant 20 in breast 22. Step 106 terminates the method of Fig. 3.

Although the embodiments described herein mainly address breast implants, the methods and systems described herein can also be used in other applications, such as in any type of light weight implants.

It will thus be appreciated that the embodiments described above are cited by way of example, and that the present invention is not limited to what has been particularly shown and described hereinabove. Rather, the scope of the present invention includes both combinations and sub-combinations of the various features described hereinabove, as well as variations and modifications thereof which would occur to persons skilled in the art upon reading the foregoing description and which are not disclosed in the prior art. Documents incorporated by reference in the present patent application are to be considered an integral part of the application except that to the extent any terms are defined in these incorporated documents in a manner that conflicts with the definitions

made explicitly or implicitly in the present specification,
only the definitions in the present specification should
be considered.

CLAIMS

1. A method for producing an implant, the method comprising:
providing a hollow biocompatible shell to be implanted
5 in an organ of a patient;
injecting, at one or more locations in the shell, at least two filling materials, wherein a mixture of at least two of the filling materials is configured to produce gas bubbles within a bulk of the mixture; and
10 forming the gas bubbles in the injected filling materials by heating the shell containing the mixture of the injected filling materials.
2. The method according to claim 1, wherein injecting the filling materials comprises mixing the at least two of the
15 filling materials to produce the mixture outside the shell, and injecting the produced mixture at the one or more locations in the shell.
3. The method according to claim 1, wherein injecting the at least two filling materials comprises injecting each of
20 the filling materials separately into the shell.
4. The method according to claim 1, wherein one of the at least two filling materials comprises a silicone polymer.
5. The method according to claim 1, wherein forming the
25 gas bubbles comprises heating the shell to a temperature above 100°C.
6. The method according to claim 1, and comprising cementing the mixture to an inner surface of the shell by heating the shell.

7. The method according to claim 1, wherein the mixture is at a liquid state prior to forming the gas bubbles, and wherein heating the shell comprises curing the mixture from the liquid state to a solid state.
- 5 8. The method according to claim 1, wherein injecting the at least two filling materials comprises injecting a first volume of the at least two filling materials at a first location in the shell, and injecting a second different volume of the at least two filling materials at a second
10 different location in the shell.
9. The method according to claim 1, and comprising injecting an additional filling material at an additional location in the shell, such that the mixture of the filling material covers at least part of an inner surface of the
15 shell.
10. The method according to claim 9, wherein injecting the additional filling material comprises injecting silicone gel.
11. An implant, comprising:
20 a hollow biocompatible shell; and
at least two filling materials,
wherein the shell is configured to be implanted in an organ of a patient, and to contain the filling materials, and wherein at least two of the filling materials are
25 configured to mix with one another and to produce gas bubbles within a bulk of a mixture of the at least two of the filling materials.
12. The implant according to claim 11, wherein one of the at least two filling materials comprises a silicone
30 polymer.

13. The implant according to claim 11, wherein the at least two of the filling materials are configured to mix with one another and to produce the gas bubbles at a temperature above 100°C.
- 5 14. The implant according to claim 11, wherein the mixture is configured to adhere to an inner surface of the shell.
15. The implant according to claim 11, wherein the mixture is configured to be at a liquid state prior to producing the gas bubbles and, when producing the gas bubbles, to
10 change state from the liquid state to a solid state.

ABSTRACT

A method for producing an implant, the method includes providing a hollow biocompatible shell to be implanted in an organ of a patient. At least two filling materials are
5 injected at one or more locations in the shell, such that a mixture of at least two of the filling materials is configured to produce gas bubbles within a bulk of the mixture. The gas bubbles are formed in the injected filling materials by heating the shell containing the mixture of
10 the injected filling materials.

TRANSMITTAL FOR POWER OF ATTORNEY TO ONE OR MORE REGISTERED PRACTITIONERS

NOTE: This form is to be submitted with the Power of Attorney by Applicant form (PTO/AIA/82B) to identify the application to which the Power of Attorney is directed, in accordance with 37 CFR 1.5, unless the application number and filing date are identified in the Power of Attorney by Applicant form. If neither form PTO/AIA/82A nor form PTO/AIA82B identifies the application to which the Power of Attorney is directed, the Power of Attorney will not be recognized in the application.

Application Number	Unassigned
Filing Date	Filed Herewith
First Named Inventor	Assaf Govari
Title	A LIGHTWEIGHT BREAST IMPLANT
Art Unit	Unassigned
Examiner Name	Unassigned
Attorney Docket Number	BIO5896USNP

SIGNATURE of Applicant or Patent Practitioner			
Signature	/Louis J. Capezzuto/	Date (Optional)	22 May 2018
Name	Louis J. Capezzuto	Registration Number	37,107
Title (if Applicant is a juristic entity)			
Applicant Name (if Applicant is a juristic entity)			
NOTE: This form must be signed in accordance with 37 CFR 1.33. See 37 CFR 1.4(d) for signature requirements and certifications. If more than one applicant, use multiple forms.			
☒ *Total of 1 forms are submitted.			

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

POWER OF ATTORNEY BY APPLICANT

I hereby revoke all previous powers of attorney given in the application identified in either the attached transmittal letter or the boxes below.

Table with 2 columns: Application Number, Filing Date

(Note: The boxes above may be left blank if information is provided on form PTO/AIA/82A.)

I hereby appoint the Patent Practitioner(s) associated with the following Customer Number as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above:

27777

OR

I hereby appoint Practitioner(s) named in the attached list (form PTO/AIA/82C) as my/our attorney(s) or agent(s), and to transact all business in the United States Patent and Trademark Office connected therewith for the patent application referenced in the attached transmittal letter (form PTO/AIA/82A) or identified above. (Note: Complete form PTO/AIA/82C.)

Please recognize or change the correspondence address for the application identified in the attached transmittal letter or the boxes above to:

The address associated with the above-mentioned Customer Number

OR

The address associated with Customer Number:

OR

Form with fields: Firm or Individual Name, Address, City, State, Zip, Country, Telephone, Email

I am the Applicant (if the Applicant is a juristic entity, list the Applicant name in the box):

BIOSENSE WEBSTER (ISRAEL) LTD.

- Inventor or Joint Inventor (title not required below)
Legal Representative of a Deceased or Legally Incapacitated Inventor (title not required below)
Assignee or Person to Whom the Inventor is Under an Obligation to Assign (provide signer's title if applicant is a juristic entity)
Person Who Otherwise Shows Sufficient Proprietary Interest (e.g., a petition under 37 CFR 1.46(b)(2) was granted in the application or is concurrently being filed with this document) (provide signer's title if applicant is a juristic entity)

SIGNATURE of Applicant for Patent

The undersigned (whose title is supplied below) is authorized to act on behalf of the applicant (e.g., where the applicant is a juristic entity).

Form with fields: Signature, Name, Title, Date (Optional)

NOTE: Signature - This form must be signed by the applicant in accordance with 37 CFR 1.33. See 37 CFR 1.4 for signature requirements and certifications. If more than one applicant, use multiple forms.

Total of 1 forms are submitted.

This collection of information is required by 37 CFR 1.131, 1.32, and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

POWER OF ATTORNEY BY APPLICANT

No more than ten (10) patent practitioners total may be appointed as set forth below by name and registration number. This page need not be submitted if appointing the Patent Practitioner(s) associated with a Customer Number (see form PTO/AIA/82B):

Name	Registration Number

Privacy Act Statement

The **Privacy Act of 1974 (P.L. 93-579)** requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.




FIG. 1





FIG. 3

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	BIO5896USNP
		Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT		
The application data sheet is part of the provisional or nonprovisional application for which it is being submitted. The following form contains the bibliographic data arranged in a format specified by the United States Patent and Trademark Office as outlined in 37 CFR 1.76. This document may be completed electronically and submitted to the Office in electronic format using the Electronic Filing System (EFS) or the document may be printed and included in a paper filed application.			

Secrecy Order 37 CFR 5.2:

☐ Portions or all of the application associated with this Application Data Sheet may fall under a Secrecy Order pursuant to 37 CFR 5.2 (Paper filers only. Applications that fall under Secrecy Order may not be filed electronically.)

Inventor Information:

Inventor	1				Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Assaf		Govari		
Residence Information (Select One) US Residency • Non US Residency Active US Military Service					
City	Haifa	Country of Residence ⁱ		L	
Mailing Address of Inventor:					
Address 1		Biosense Webster (Israel) Ltd.			
Address 2		4 Hatnufa Street, P.O. Box 275			
City	Yokneam	State/Province			
Postal Code	2066717	Country ⁱ	IL		
Inventor	2				Remove
Legal Name					
Prefix	Given Name	Middle Name	Family Name	Suffix	
	Yehuda		Algawi		
Residence Information (Select One) US Residency • Non US Residency Active US Military Service					
City	Binyamina	Country of Residence ⁱ		L	
Mailing Address of Inventor:					
Address 1		Biosense Webster (Israel) Ltd.			
Address 2		4 Hatnufa Street, P.O. Box 275			
City	Yokneam	State/Province			
Postal Code	2066717	Country ⁱ	IL		
All Inventors Must Be Listed - Additional Inventor Information blocks may be generated within this form by selecting the Add button.					
					Add

Correspondence Information:

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	BIO5896USNP
		Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT		

Enter either Customer Number or complete the Correspondence Information section below.
For further information see 37 CFR 1.33(a).

☐ An Address is being provided for the correspondence information of this application.

Customer Number	27777		
Email Address	JNJUSPATENT@CORUS.JNJ.COM	Add Email	Remove Email

Application Information:

Title of the Invention	A LIGHTWEIGHT BREAST IMPLANT		
Attorney Docket Number	BIO5896USNP	Small Entity Status Claimed	☐
Application Type	Nonprovisional		
Subject Matter	Utility		
Total Number of Drawing Sheets (if any)	2	Suggested Figure for Publication (if any)	

Filing By Reference:

Only complete this section when filing an application by reference under 35 U.S.C. 111(c) and 37 CFR 1.57(a). Do not complete this section if application papers including a specification and any drawings are being filed. Any domestic benefit or foreign priority information must be provided in the appropriate section(s) below (i.e., "Domestic Benefit/National Stage Information" and "Foreign Priority Information").

For the purposes of a filing date under 37 CFR 1.53(b), the description and any drawings of the present application are replaced by this reference to the previously filed application, subject to conditions and requirements of 37 CFR 1.57(a).

Application number of the previously filed application	Filing date (YYYY-MM-DD)	Intellectual Property Authority or Country

Publication Information:

☐ Request Early Publication (Fee required at time of Request 37 CFR 1.219)

☐ **Request Not to Publish.** I hereby request that the attached application not be published under 35 U.S.C. 122(b) and certify that the invention disclosed in the attached application **has not and will not** be the subject of an application filed in another country, or under a multilateral international agreement, that requires publication at eighteen months after filing.

Representative Information:

Representative information should be provided for all practitioners having a power of attorney in the application. Providing this information in the Application Data Sheet does not constitute a power of attorney in the application (see 37 CFR 1.32). Either enter Customer Number or complete the Representative Name section below. If both sections are completed the customer Number will be used for the Representative Information during processing.

Please Select One:	☒ Customer Number	☐ US Patent Practitioner	☐ Limited Recognition (37 CFR 11.9)
Customer Number	27777		

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	BIO5896USNP
		Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT		

Domestic Benefit/National Stage Information:

This section allows for the applicant to either claim benefit under 35 U.S.C. 119(e), 120, 121, 365(c), or 386(c) or indicate National Stage entry from a PCT application. Providing benefit claim information in the Application Data Sheet constitutes the specific reference required by 35 U.S.C. 119(e) or 120, and 37 CFR 1.78.
When referring to the current application, please leave the "Application Number" field blank.

Prior Application Status		Remove	
Application Number	Continuity Type	Prior Application Number	Filing or 371(c) Date (YYYY-MM-DD)
Additional Domestic Benefit/National Stage Data may be generated within this form by selecting the Add button.			Add

Foreign Priority Information:

This section allows for the applicant to claim priority to a foreign application. Providing this information in the application data sheet constitutes the claim for priority as required by 35 U.S.C. 119(b) and 37 CFR 1.55. When priority is claimed to a foreign application that is eligible for retrieval under the priority document exchange program (PDX)ⁱ the information will be used by the Office to automatically attempt retrieval pursuant to 37 CFR 1.55(i)(1) and (2). Under the PDX program, applicant bears the ultimate responsibility for ensuring that a copy of the foreign application is received by the Office from the participating foreign intellectual property office, or a certified copy of the foreign priority application is filed, within the time period specified in 37 CFR 1.55(g)(1).

			Remove
Application Number	Country ⁱ	Filing Date (YYYY-MM-DD)	Access Code ⁱ (if applicable)
Additional Foreign Priority Data may be generated within this form by selecting the Add button.			Add

Statement under 37 CFR 1.55 or 1.78 for AIA (First Inventor to File) Transition Applications

☐ This application (1) claims priority to or the benefit of an application filed before March 16, 2013 and (2) also contains, or contained at any time, a claim to a claimed invention that has an effective filing date on or after March 16, 2013.
NOTE: By providing this statement under 37 CFR 1.55 or 1.78, this application, with a filing date on or after March 16, 2013, will be examined under the first inventor to file provisions of the AIA.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	BIO5896USNP
		Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT		

Authorization or Opt-Out of Authorization to Permit Access:

When this Application Data Sheet is properly signed and filed with the application, applicant has provided written authority to permit a participating foreign intellectual property (IP) office access to the instant application-as-filed (see paragraph A in subsection 1 below) and the European Patent Office (EPO) access to any search results from the instant application (see paragraph B in subsection 1 below).

Should applicant choose not to provide an authorization identified in subsection 1 below, applicant **must opt-out** of the authorization by checking the corresponding box A or B or both in subsection 2 below.

NOTE: This section of the Application Data Sheet is **ONLY** reviewed and processed with the **INITIAL** filing of an application. After the initial filing of an application, an Application Data Sheet cannot be used to provide or rescind authorization for access by a foreign IP office(s). Instead, Form PTO/SB/39 or PTO/SB/69 must be used as appropriate.

1. Authorization to Permit Access by a Foreign Intellectual Property Office(s)

A. Priority Document Exchange (PDX) - Unless box A in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the European Patent Office (EPO), the Japan Patent Office (JPO), the Korean Intellectual Property Office (KIPO), the State Intellectual Property Office of the People's Republic of China (SIPO), the World Intellectual Property Organization (WIPO), and any other foreign intellectual property office participating with the USPTO in a bilateral or multilateral priority document exchange agreement in which a foreign application claiming priority to the instant patent application is filed, access to: (1) the instant patent application-as-filed and its related bibliographic data, (2) any foreign or domestic application to which priority or benefit is claimed by the instant application and its related bibliographic data, and (3) the date of filing of this Authorization. See 37 CFR 1.14(h)(1).

B. Search Results from U.S. Application to EPO - Unless box B in subsection 2 (opt-out of authorization) is checked, the undersigned hereby **grants the USPTO authority** to provide the EPO access to the bibliographic data and search results from the instant patent application when a European patent application claiming priority to the instant patent application is filed. See 37 CFR 1.14(h)(2).

The applicant is reminded that the EPO's Rule 141(1) EPC (European Patent Convention) requires applicants to submit a copy of search results from the instant application without delay in a European patent application that claims priority to the instant application.

2. Opt-Out of Authorizations to Permit Access by a Foreign Intellectual Property Office(s)

☐ A. Applicant **DOES NOT** authorize the USPTO to permit a participating foreign IP office access to the instant application-as-filed. If this box is checked, the USPTO will not be providing a participating foreign IP office with any documents and information identified in subsection 1A above.

☐ B. Applicant **DOES NOT** authorize the USPTO to transmit to the EPO any search results from the instant patent application. If this box is checked, the USPTO will not be providing the EPO with search results from the instant application.

NOTE: Once the application has published or is otherwise publicly available, the USPTO may provide access to the application in accordance with 37 CFR 1.14.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	BIO5896USNP
		Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT		

Applicant Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Applicant	1	Remove
-----------	---	--------

If the applicant is the inventor (or the remaining joint inventor or inventors under 37 CFR 1.45), this section should not be completed. The information to be provided in this section is the name and address of the legal representative who is the applicant under 37 CFR 1.43; or the name and address of the assignee, person to whom the inventor is under an obligation to assign the invention, or person who otherwise shows sufficient proprietary interest in the matter who is the applicant under 37 CFR 1.46. If the applicant is an applicant under 37 CFR 1.46 (assignee, person to whom the inventor is obligated to assign, or person who otherwise shows sufficient proprietary interest) together with one or more joint inventors, then the joint inventor or inventors who are also the applicant should be identified in this section.

Clear

☒ Assignee	Legal Representative under 35 U.S.C. 117	Joint Inventor
---	--	----------------

Person to whom the inventor is obligated to assign.	Person who shows sufficient proprietary interest
---	--

If applicant is the legal representative, indicate the authority to file the patent application, the inventor is:

Name of the Deceased or Legally Incapacitated Inventor:

If the Applicant is an Organization check here. ☒

Organization Name	Biosense Webster (Israel) Ltd.		
-------------------	--------------------------------	--	--

Mailing Address Information For Applicant:

Address 1	4 Hatnufa Street		
Address 2	P.O. Box 275		
City	Yokneam	State/Province	
Country	IL	Postal Code	2066717
Phone Number		Fax Number	
Email Address			

Additional Applicant Data may be generated within this form by selecting the Add button.

Add

Assignee Information including Non-Applicant Assignee Information:

Providing assignment information in this section does not substitute for compliance with any requirement of part 3 of Title 37 of CFR to have an assignment recorded by the Office.

Application Data Sheet 37 CFR 1.76		Attorney Docket Number	BIO5896USNP
		Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT		

Assignee	1			
Complete this section if assignee information, including non-applicant assignee information, is desired to be included on the patent application publication. An assignee-applicant identified in the "Applicant Information" section will appear on the patent application publication as an applicant. For an assignee-applicant, complete this section only if identification as an assignee is also desired on the patent application publication.				
				Remove
If the Assignee or Non-Applicant Assignee is an Organization check here.				☐
Prefix	Given Name	Middle Name	Family Name	Suffix
Mailing Address Information For Assignee including Non-Applicant Assignee:				
Address 1				
Address 2				
City		State/Province		
Country ⁱ		Postal Code		
Phone Number		Fax Number		
Email Address				
Additional Assignee or Non-Applicant Assignee Data may be generated within this form by selecting the Add button.				Add

Signature:

NOTE: This Application Data Sheet must be signed in accordance with 37 CFR 1.33(b). However, if this Application Data Sheet is submitted with the **INITIAL** filing of the application and either box A or B is **not** checked in subsection 2 of the "Authorization or Opt-Out of Authorization to Permit Access" section, then this form must also be signed in accordance with 37 CFR 1.14(c).

This Application Data Sheet **must** be signed by a patent practitioner if one or more of the applicants is a juristic entity (e.g., corporation or association). If the applicant is two or more joint inventors, this form must be signed by a patent practitioner, **all** joint inventors who are the applicant, or one or more joint inventor-applicants who have been given power of attorney (e.g., see USPTO Form PTO/AIA/81) on behalf of **all** joint inventor-applicants.

See 37 CFR 1.4(d) for the manner of making signatures and certifications.

Signature	/Eugene L. Szczecina, Jr./		Date (YYYY-MM-DD)	2018-05-22	
First Name	Eugene L.	Last Name	Szczecina, Jr.	Registration Number	35,029
Additional Signature may be generated within this form by selecting the Add button.					Add

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Application Data Sheet 37 CFR 1.76	Attorney Docket Number	BIO5896USNP
	Application Number	
Title of Invention	A LIGHTWEIGHT BREAST IMPLANT	

This collection of information is required by 37 CFR 1.76. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 23 minutes to complete, including gathering, preparing, and submitting the completed application data sheet form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patent application or patent. Accordingly, pursuant to the requirements of the Act, please be advised that: (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) furnishing of the information solicited is voluntary; and (3) the principal purpose for which the information is used by the U.S. Patent and Trademark Office is to process and/or examine your submission related to a patent application or patent. If you do not furnish the requested information, the U.S. Patent and Trademark Office may not be able to process and/or examine your submission, which may result in termination of proceedings or abandonment of the application or expiration of the patent.

The information provided by you in this form will be subject to the following routine uses:

1. The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these records.
2. A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiations.
3. A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
4. A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552a(m).
5. A record related to an International Application filed under the Patent Cooperation Treaty in this system of records may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant to the Patent Cooperation Treaty.
6. A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or his/her designee, during an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2904 and 2906. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
8. A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S.C. 122(b) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filed in an application which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inspections or an issued patent.
9. A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: A LIGHTWEIGHT BREAST IMPLANT

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors) _____,

or

☒ The United States application or PCT international application
number 15/986,109 filed on May 22, 2018.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Biosense Webster (Israel) Ltd.
4 Hatnufa Street
Yokneam 2066717 Israel

A corporation of the state or country of Israel

(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

ASSAF GOVARI

Signature

AC

Date

May, 14, 2019

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: A LIGHTWEIGHT BREAST IMPLANT

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors) _____,

or

☒ The United States application or PCT international application
number 15/986,109 filed on May 22, 2018.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Biosense Webster (Israel) Ltd.
4 Hatnufa Street
Yokneam 2066717 Israel

A corporation of the state or country of Israel

(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.


LEGAL NAME OF INVENTOR

YEHUDA ALGAWI

Signature



Date



COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: A LIGHTWEIGHT BREAST IMPLANT

This declaration and assignment is directed to:

☐ The attached or filed herewith application of (list of named inventors) _____,

or

☒ The United States application or PCT international application
number 15/986,109 filed on May 22, 2018.

Declaration

As the below named inventor, I hereby declare that:

The above-identified application ("Application") was made or authorized by me.

I believe that I am the original inventor or an original inventor of a claimed invention or discovery in the Application.

I have reviewed and understood the contents of the Application, including the claims, and I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of this Application in the United States of America.

I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.

Assignment

Biosense Webster (Israel) Ltd.
4 Hatnufa Street
Yokneam 2066717 Israel

A corporation of the state or country of Israel

(hereinafter designated as the "Assignee"),

☐ I hereby acknowledge that I have assigned the above-identified invention by previous assignment (attached hereto) to Assignee which is hereby conformed for recordation in the US Patent Office and I confirm I have and do assign and transfer:

or

☒ For good and valuable consideration, the sufficiency of which is acknowledged, I hereby assign and transfer and/or have assigned and transferred to Assignee:

my entire right, title, and interest in, to, and under the Application, including all priority rights for other countries arising therefrom and the right to claim priority to the Application, all inventions or discoveries therein disclosed, and any and all Letters Patent of the United States, European Patent Office and of all other countries, which may be granted for such inventions or discoveries, or any of them, all such inventions or discoveries and all rights in such Application including any and all provisionals, substitutions, divisions, and continuations thereof, and to all Letters Patent that may be granted for said inventions and discoveries, and in and to all extensions, supplementary protection certificates, reexaminations, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use and enjoyment to the full end of the term or terms for which such Letters Patent may be granted, as fully and entirely as the same would have been held and enjoyed by me had this assignment and sale not been made.

I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

LEGAL NAME OF INVENTOR

ILYA SITNITSKY

Signature



Date

May, 14, 2019

TRADUCCIÓN OFICIAL No. 133A/CKM REALIZADA POR DIEGO F. VARGAS ZAMORA, TRADUCTOR E INTÉRPRETE OFICIAL INGLÉS-ESPAÑOL, RECONOCIDO POR EL MINISTERIO DE JUSTICIA E INSCRITO ANTE EL MINISTERIO DE RELACIONES EXTERIORES.

REFERENCIA DEL APODERADO NÚMERO: BIO5896USNP
Solicitud Estados Unidos No. 15/986,109

DECLARACIÓN Y CESIÓN CONJUNTA

Título de la Invención: UN IMPLANTE MAMARIO DE PESO LIGERO

La presente declaración y cesión se relaciona con:

☐ La solicitud adjunta o la cual se presenta con este documento (lista de inventores nombrados) _____
o

☒ La solicitud de los Estados Unidos o la solicitud internacional PCT número 15/986,109 presentada el 22 de mayo de 2018

Declaración

Como inventor mencionado a continuación, por el presente declaro que:

La anterior solicitud ("Solicitud") fue presentada o autorizada por el suscrito.

Considero que soy el inventor original o uno de los inventores originales de una invención o descubrimiento reivindicado en la Solicitud.

He revisado y comprendido el contenido de la Solicitud, incluyendo las reivindicaciones, y reconozco la obligación de divulgar la información que sea sustancial para la patentabilidad, según se define en el Artículo 1.56 del

DIEGO F. VARGAS Z.
TRADUCTOR E INTÉRPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1994
MINISTERIO DE JUSTICIA

Título 37 del Código de Regulaciones Federales de los Estados Unidos, para la presentación de esta Solicitud en los Estados Unidos de América.

Por el presente reconozco que cualquier manifestación falsa deliberada, realizada en la presente declaración, será castigada de conformidad con el Artículo 1001 del Título 18 del Código de los Estados Unidos, con multa o encarcelamiento no superior a los cinco (5) años o ambos, para la presentación de esta solicitud en los Estados Unidos de América.

Cesión

Biosense Webster (Israel) Ltd.

4 Hatnufa Street

Yokneam, 2066717 Israel

Una sociedad del estado o país de Israel
(denominada en adelante como la "Cesionaria"),

☐ Por el presente reconozco que he cedido la invención identificada anteriormente mediante la cesión precedente (adjunta al presente) a la Cesionaria, la cual se confirma por el presente, para su inscripción ante la Oficina de Marcas y Patentes de los Estados Unidos y confirmo que he cedido y transferido y efectivamente cedo y transfiero:

o

☒ Por contraprestación legal y válida, la suficiencia de la cual se reconoce por el presente, por medio de este instrumento cedo y transfiero y/o he cedido y transferido a la Cesionaria;

DIEGO F. VARRAS Z.
TRADUCTOR E INTERPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1992²
MINISTERIO DE JUSTICIA

todo mi derecho, título e interés en, para y según la Solicitud, incluyendo todos los derechos de prioridad para otros países que surjan de la misma y el derecho a reivindicar prioridad a la Solicitud, a todas las invenciones o descubrimientos divulgados en esta, y a cualquier y todas las Patentes de Invención de los Estados Unidos, de la Oficina Europea de Patentes y de todos los demás países, que se lleguen a otorgar para dichas invenciones o descubrimientos, o particularmente a una de estas, a todas dichas invenciones o descubrimientos, así como todos los derechos en dicha Solicitud, incluyendo cualquier y todas las solicitudes provisionales, de sustitución, de división y continuación de la misma y a todas las Patentes de Invención que se lleguen a otorgar a dichas invenciones y descubrimientos, así como en y a todas las prórrogas, certificados complementarios de protección, nuevos exámenes, renovaciones y reexpediciones de las mismas, para que sean tenidas y disfrutadas por parte de la Cesionaria para su propio uso y beneficio, hasta el vencimiento del término o términos para los cuales dichas Patentes de Invención se lleguen a otorgar, tan cabal y totalmente como estas habrían sido tenidas y disfrutadas por parte mía, si no se hubiere realizado esta cesión y venta.

Me comprometo a firmar todos los documentos que sean necesarios con respecto a la Solicitud ante la Oficina de Marcas y Patentes de los Estados Unidos, la Oficina Europea de Patentes, cualquier otra oficina de patentes y de conformidad con el Tratado de Cooperación de Patentes, así como cualquier solicitud de continuación, divisional o reexpedición de las mismas, cualquier nuevo examen de cualquiera de dichas solicitudes y cualquier prórroga del

DIEGO F. VARELAS Z.
TRADUCTOR E INTERPRETE JURISDICCIONAL
ESPAÑOL-INGLES - INGLES-ESPAÑOL
RES. 0001 DE ENERO 4 DE 1995
MINISTERIO DE JUSTICIA

término de patente o certificado complementario de protección para cualquiera de dichas solicitudes y también a suscribir cesiones independientes con respecto a dichas solicitudes que la Cesionaria pueda considerar conveniente o necesaria.

Me comprometo a firmar todos los documentos que sean necesarios en relación con cualquier litigio u otra clase de proceso judicial en los Estados Unidos o en otro país o en cualquier proceso administrativo ante la Oficina de Marcas y Patentes de los Estados Unidos, ante la Oficina Europea de Patentes o ante cualquier otra oficina de patentes, o de conformidad con el Tratado de Cooperación de Patentes, relativo a la(s) Solicitud(es) o cualquier solicitud de continuación, divisional o de reexpedición de las mismas o cualquier nuevo examen de cualquiera de dichas solicitudes o de cualquier Patente de Invención expedida con base en estas o cualquier prórroga al término de patente o certificado de protección complementaria, para cualquiera de dichas solicitudes y a cooperar con la Cesionaria, de cualquier forma que sea posible, para obtener pruebas y avanzar en el trámite de dichos litigios o procesos.

Me comprometo a firmar todos los instrumentos y documentos y a ejecutar cualquier acto que pueda ser necesario con respecto a las reivindicaciones o disposiciones de la Convención Internacional para la Protección de la Propiedad Industrial o acuerdos similares.

Me comprometo a realizar todos los demás actos que puedan ser necesarios o convenientes, en opinión de la Cesionaria, para asegurar el otorgamiento de Patentes de Invención a la Cesionaria o a su nominataria, en los Estados Unidos, por parte de la Oficina Europea de Patentes y en

DIEGO F. VARGAS Z.
TRADUCTOR E INTERPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1997
MINISTERIO DE JUSTICIA

todos los demás países en donde la Cesionaria desee patentar dichas invenciones o descubrimientos o uno cualquiera de ellos, con especificaciones y reivindicaciones en la forma que apruebe la Cesionaria y para investir y confirmar en la Cesionaria o en su nominataria el pleno y total título legal y en equidad a todas dichas Patentes de Invención.

Por el presente (i) autorizo y solicito al Comisionado de Marcas y Patentes de los Estados Unidos a expedir cualquiera y todas las Patentes de Invención de los Estados Unidos, que resulten de la Solicitud o de cualquier solicitud divisional, de continuación o de reexpedición y de cualquier nuevo examen de cualquiera de dichas solicitudes a la Cesionaria, y (ii) garantizo que poseo todo el derecho de enajenar la participación cedida por el presente y que no he suscrito ni suscribiré ningún acuerdo que esté en conflicto con el presente.

Por el presente otorgo poder al apoderado que aparece en el registro, para inscribir en la presente cesión cualquier identificación adicional que pueda ser necesaria o conveniente, con el fin de obtener la inscripción legal de este documento.

NOMBRE LEGAL DEL INVENTOR

Assaf GOVARI

Firma Ilegible
Firma

14 de mayo de 2019
Fecha

FIN DE LA TRADUCCIÓN

Bogotá D.C., 24 de julio de 2019

Es traducción fiel y completa del documento original realizada por: DIEGO F. VARGAS ZAMORA, Traductor e Intérprete Oficial Según Resolución No. 0001 de 1999 Ministerio de Justicia de Colombia.

DIEGO F. VARGAS Z.
TRADUCTOR E INTÉRPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1999
MINISTERIO DE JUSTICIA

TRADUCCIÓN OFICIAL No. 133B/CKM REALIZADA POR DIEGO F. VARGAS ZAMORA, TRADUCTOR E INTÉRPRETE OFICIAL INGLÉS-ESPAÑOL, RECONOCIDO POR EL MINISTERIO DE JUSTICIA E INSCRITO ANTE EL MINISTERIO DE RELACIONES EXTERIORES.

REFERENCIA DEL APODERADO NÚMERO: BIO5896USNP
Solicitud Estados Unidos No. 15/986,109

DECLARACIÓN Y CESIÓN CONJUNTA

Título de la Invención: UN IMPLANTE MAMARIO DE PESO LIGERO

La presente declaración y cesión se relaciona con:

☐ La solicitud adjunta o la cual se presenta con este documento (lista de inventores nombrados) _____

o

☒ La solicitud de los Estados Unidos o la solicitud internacional PCT número 15/986,109 presentada el 22 de mayo de 2018

Declaración

Como inventor mencionado a continuación, por el presente declaro que:

La anterior solicitud ("Solicitud") fue presentada o autorizada por el suscrito.

Considero que soy el inventor original o uno de los inventores originales de una invención o descubrimiento reivindicado en la Solicitud.

He revisado y comprendido el contenido de la Solicitud, incluyendo las reivindicaciones, y reconozco la obligación de divulgar la información que sea sustancial para la patentabilidad, según se define en el Artículo 1.56 del

DIEGO F. VARGAS Z.
TRADUCTOR E INTÉRPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1974
MINISTERIO DE JUSTICIA

Título 37 del Código de Regulaciones Federales de los Estados Unidos, para la presentación de esta Solicitud en los Estados Unidos de América.

Por el presente reconozco que cualquier manifestación falsa deliberada, realizada en la presente declaración, será castigada de conformidad con el Artículo 1001 del Título 18 del Código de los Estados Unidos, con multa o encarcelamiento no superior a los cinco (5) años o ambos, para la presentación de esta solicitud en los Estados Unidos de América.

Cesión

Biosense Webster (Israel) Ltd.

4 Hatnufa Street

Yokneam, 2066717 Israel

Una sociedad del estado o país de Israel
(denominada en adelante como la "Cesionaria"),

☐ Por el presente reconozco que he cedido la invención identificada anteriormente mediante la cesión precedente (adjunta al presente) a la Cesionaria, la cual se confirma por el presente, para su inscripción ante la Oficina de Marcas y Patentes de los Estados Unidos y confirmo que he cedido y transferido y efectivamente cedo y transfiero:

o

☒ Por contraprestación legal y válida, la suficiencia de la cual se reconoce por el presente, por medio de este instrumento cedo y transfiero y/o he cedido y transferido a la Cesionaria;

DIEGO F. VARGAS Z.
TRADUCTOR E INTERPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1998
MINISTERIO DE JUSTICIA

todo mi derecho, título e interés en, para y según la Solicitud, incluyendo todos los derechos de prioridad para otros países que surjan de la misma y el derecho a reivindicar prioridad a la Solicitud, a todas las invenciones o descubrimientos divulgados en esta, y a cualquier y todas las Patentes de Invención de los Estados Unidos, de la Oficina Europea de Patentes y de todos los demás países, que se lleguen a otorgar para dichas invenciones o descubrimientos, o particularmente a una de estas, a todas dichas invenciones o descubrimientos, así como todos los derechos en dicha Solicitud, incluyendo cualquier y todas las solicitudes provisionales, de sustitución, de división y continuación de la misma y a todas las Patentes de Invención que se lleguen a otorgar a dichas invenciones y descubrimientos, así como en y a todas las prórrogas, certificados complementarios de protección, nuevos exámenes, renovaciones y reexpediciones de las mismas, para que sean tenidas y disfrutadas por parte de la Cesionaria para su propio uso y beneficio, hasta el vencimiento del término o términos para los cuales dichas Patentes de Invención se lleguen a otorgar, tan cabal y totalmente como estas habrían sido tenidas y disfrutadas por parte mía, si no se hubiere realizado esta cesión y venta.

Me comprometo a firmar todos los documentos que sean necesarios con respecto a la Solicitud ante la Oficina de Marcas y Patentes de los Estados Unidos, la Oficina Europea de Patentes, cualquier otra oficina de patentes y de conformidad con el Tratado de Cooperación de Patentes, así como cualquier solicitud de continuación, divisional o reexpedición de las mismas, cualquier nuevo examen de cualquiera de dichas solicitudes y cualquier prórroga del

DIEGO F. VARELA Z.

TRADUCTOR E INTERPRETE JURADO

ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL

RES. 0001 DE ENERO 4 DE 1999

MINISTERIO DE JUSTICIA

término de patente o certificado complementario de protección para cualquiera de dichas solicitudes y también a suscribir cesiones independientes con respecto a dichas solicitudes que la Cesionaria pueda considerar conveniente o necesaria.

Me comprometo a firmar todos los documentos que sean necesarios en relación con cualquier litigio u otra clase de proceso judicial en los Estados Unidos o en otro país o en cualquier proceso administrativo ante la Oficina de Marcas y Patentes de los Estados Unidos, ante la Oficina Europea de Patentes o ante cualquier otra oficina de patentes, o de conformidad con el Tratado de Cooperación de Patentes, relativo a la(s) Solicitud(es) o cualquier solicitud de continuación, divisional o de reexpedición de las mismas o cualquier nuevo examen de cualquiera de dichas solicitudes o de cualquier Patente de Invención expedida con base en estas o cualquier prórroga al término de patente o certificado de protección complementaria, para cualquiera de dichas solicitudes y a cooperar con la Cesionaria, de cualquier forma que sea posible, para obtener pruebas y avanzar en el trámite de dichos litigios o procesos.

Me comprometo a firmar todos los instrumentos y documentos y a ejecutar cualquier acto que pueda ser necesario con respecto a las reivindicaciones o disposiciones de la Convención Internacional para la Protección de la Propiedad Industrial o acuerdos similares.

Me comprometo a realizar todos los demás actos que puedan ser necesarios o convenientes, en opinión de la Cesionaria, para asegurar el otorgamiento de Patentes de Invención a la Cesionaria o a su nominataria, en los Estados Unidos, por parte de la Oficina Europea de Patentes y en

DIEGO F. VARGAS
4
TRADUCTOR E INTERPRETE
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1976
MINISTERIO DE JUSTICIA

todos los demás países en donde la Cesionaria desee patentar dichas invenciones o descubrimientos o uno cualquiera de ellos, con especificaciones y reivindicaciones en la forma que apruebe la Cesionaria y para investir y confirmar en la Cesionaria o en su nominataria el pleno y total título legal y en equidad a todas dichas Patentes de Invención.

Por el presente (i) autorizo y solicito al Comisionado de Marcas y Patentes de los Estados Unidos a expedir cualquiera y todas las Patentes de Invención de los Estados Unidos, que resulten de la Solicitud o de cualquier solicitud divisional, de continuación o de reexpedición y de cualquier nuevo examen de cualquiera de dichas solicitudes a la Cesionaria, y (ii) garantizo que poseo todo el derecho de enajenar la participación cedida por el presente y que no he suscrito ni suscribiré ningún acuerdo que esté en conflicto con el presente.

Por el presente otorgo poder al apoderado que aparece en el registro, para inscribir en la presente cesión cualquier identificación adicional que pueda ser necesaria o conveniente, con el fin de obtener la inscripción legal de este documento.

NOMBRE LEGAL DEL INVENTOR

YEHUDA ALGAWI

Firma Ilegible
Firma

14 de mayo de 2019
Fecha

FIN DE LA TRADUCCIÓN

Bogotá D.C., 24 de julio de 2019

Es traducción fiel y completa del documento original realizada por: DIEGO F. VARGAS ZAMORA, Traductor e Intérprete Oficial Según Resolución No. 0001 de 1999 Ministerio de Justicia de Colombia.

DIEGO F. VARGAS Z.
TRADUCTOR E INTÉRPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1999
MINISTERIO DE JUSTICIA

TRADUCCIÓN OFICIAL No. 133C/CKM REALIZADA POR DIEGO F. VARGAS ZAMORA, TRADUCTOR E INTÉRPRETE OFICIAL INGLÉS-ESPAÑOL, RECONOCIDO POR EL MINISTERIO DE JUSTICA E INSCRITO ANTE EL MINISTERIO DE RELACIONES EXTERIORES.

REFERENCIA DEL APODERADO NÚMERO: BIO5896USNP
Solicitud Estados Unidos No. 15/986,109

DECLARACIÓN Y CESIÓN CONJUNTA

Título de la Invención: UN IMPLANTE MAMARIO DE PESO LIGERO

La presente declaración y cesión se relaciona con:

☐ La solicitud adjunta o la cual se presenta con este documento (lista de inventores nombrados) _____
o

☒ La solicitud de los Estados Unidos o la solicitud internacional PCT número 15/986,109 presentada el 22 de mayo de 2018

Declaración

Como inventor mencionado a continuación, por el presente declaro que:

La anterior solicitud ("Solicitud") fue presentada o autorizada por el suscrito.

Considero que soy el inventor original o uno de los inventores originales de una invención o descubrimiento reivindicado en la Solicitud.

He revisado y comprendido el contenido de la Solicitud, incluyendo las reivindicaciones, y reconozco la obligación de divulgar la información que sea sustancial para la patentabilidad, según se define en el Artículo 1.56 del

DIEGO F. VARGAS Z. 1
TRADUCTOR E INTÉRPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. COM. DE ABOG. 4 DE 12

Título 37 del Código de Regulaciones Federales de los Estados Unidos, para la presentación de esta Solicitud en los Estados Unidos de América.

Por el presente reconozco que cualquier manifestación falsa deliberada, realizada en la presente declaración, será castigada de conformidad con el Artículo 1001 del Título 18 del Código de los Estados Unidos, con multa o encarcelamiento no superior a los cinco (5) años o ambos, para la presentación de esta solicitud en los Estados Unidos de América.

Cesión

Biosense Webster (Israel) Ltd.

4 Hatnufa Street

Yokneam, 2066717 Israel

Una sociedad del estado o país de Israel
(denominada en adelante como la "Cesionaria"),

☐ Por el presente reconozco que he cedido la invención identificada anteriormente mediante la cesión precedente (adjunta al presente) a la Cesionaria, la cual se confirma por el presente, para su inscripción ante la Oficina de Marcas y Patentes de los Estados Unidos y confirmo que he cedido y transferido y efectivamente cedo y transfiero:

o

☒ Por contraprestación legal y válida, la suficiencia de la cual se reconoce por el presente, por medio de este instrumento cedo y transfiero y/o he cedido y transferido a la Cesionaria;

DIEGO F. VARGAS Z.
TRADUCTOR E INTERPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1997 2
MINISTERIO DE JUSTICIA

todo mi derecho, título e interés en, para y según la Solicitud, incluyendo todos los derechos de prioridad para otros países que surjan de la misma y el derecho a reivindicar prioridad a la Solicitud, a todas las invenciones o descubrimientos divulgados en esta, y a cualquier y todas las Patentes de Invención de los Estados Unidos, de la Oficina Europea de Patentes y de todos los demás países, que se lleguen a otorgar para dichas invenciones o descubrimientos, o particularmente a una de estas, a todas dichas invenciones o descubrimientos, así como todos los derechos en dicha Solicitud, incluyendo cualquier y todas las solicitudes provisionales, de sustitución, de división y continuación de la misma y a todas las Patentes de Invención que se lleguen a otorgar a dichas invenciones y descubrimientos, así como en y a todas las prórrogas, certificados complementarios de protección, nuevos exámenes, renovaciones y reexpediciones de las mismas, para que sean tenidas y disfrutadas por parte de la Cesionaria para su propio uso y beneficio, hasta el vencimiento del término o términos para los cuales dichas Patentes de Invención se lleguen a otorgar, tan cabal y totalmente como estas habrían sido tenidas y disfrutadas por parte mía, si no se hubiere realizado esta cesión y venta.

Me comprometo a firmar todos los documentos que sean necesarios con respecto a la Solicitud ante la Oficina de Marcas y Patentes de los Estados Unidos, la Oficina Europea de Patentes, cualquier otra oficina de patentes y de conformidad con el Tratado de Cooperación de Patentes, así como cualquier solicitud de continuación, divisional o reexpedición de las mismas, cualquier nuevo examen de cualquiera de dichas solicitudes y cualquier prórroga del

DIEGO F. VARGAS Z
TRADUCTOR E INTERPRETE JURADO
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE FEBRERO 4 DE 1974

término de patente o certificado complementario de protección para cualquiera de dichas solicitudes y también a suscribir cesiones independientes con respecto a dichas solicitudes que la Cesionaria pueda considerar conveniente o necesaria.

Me comprometo a firmar todos los documentos que sean necesarios en relación con cualquier litigio u otra clase de proceso judicial en los Estados Unidos o en otro país o en cualquier proceso administrativo ante la Oficina de Marcas y Patentes de los Estados Unidos, ante la Oficina Europea de Patentes o ante cualquier otra oficina de patentes, o de conformidad con el Tratado de Cooperación de Patentes, relativo a la(s) Solicitud(es) o cualquier solicitud de continuación, divisional o de reexpedición de las mismas o cualquier nuevo examen de cualquiera de dichas solicitudes o de cualquier Patente de Invención expedida con base en estas o cualquier prórroga al término de patente o certificado de protección complementaria, para cualquiera de dichas solicitudes y a cooperar con la Cesionaria, de cualquier forma que sea posible, para obtener pruebas y avanzar en el trámite de dichos litigios o procesos.

Me comprometo a firmar todos los instrumentos y documentos y a ejecutar cualquier acto que pueda ser necesario con respecto a las reivindicaciones o disposiciones de la Convención Internacional para la Protección de la Propiedad Industrial o acuerdos similares.

Me comprometo a realizar todos los demás actos que puedan ser necesarios o convenientes, en opinión de la Cesionaria, para asegurar el otorgamiento de Patentes de Invención a la Cesionaria o a su nominataria, en los Estados Unidos, por parte de la Oficina Europea de Patentes y en

todos los demás países en donde la Cesionaria desee patentar dichas invenciones o descubrimientos o uno cualquiera de ellos, con especificaciones y reivindicaciones en la forma que apruebe la Cesionaria y para investir y confirmar en la Cesionaria o en su nominataria el pleno y total título legal y en equidad a todas dichas Patentes de Invención.

Por el presente (i) autorizo y solicito al Comisionado de Marcas y Patentes de los Estados Unidos a expedir cualquiera y todas las Patentes de Invención de los Estados Unidos, que resulten de la Solicitud o de cualquier solicitud divisional, de continuación o de reexpedición y de cualquier nuevo examen de cualquiera de dichas solicitudes a la Cesionaria, y (ii) garantizo que poseo todo el derecho de enajenar la participación cedida por el presente y que no he suscrito ni suscribiré ningún acuerdo que esté en conflicto con el presente.

Por el presente otorgo poder al apoderado que aparece en el registro, para inscribir en la presente cesión cualquier identificación adicional que pueda ser necesaria o conveniente, con el fin de obtener la inscripción legal de este documento.

NOMBRE LEGAL DEL INVENTOR

ILYA SITNITSKY

Firma Ilegible
Firma

14 de mayo de 2019
Fecha

FIN DE LA TRADUCCIÓN

Bogotá D.C., 24 de julio de 2019

Es traducción fiel y completa del documento original realizada por: DIEGO F. VARGAS ZAMORA,
Traductor e Intérprete Oficial Según Resolución No. 0001 de 1999 Ministerio de Justicia de Colombia.

DIEGO F. VARGAS Z
TRADUCTOR E INTERPRETE OFICIAL
ESPAÑOL - INGLÉS - INGLÉS - ESPAÑOL
RES. 0001 DE ENERO 4 DE 1999
MINISTERIO DE JUSTICIA